ArticleBMC infectious diseases2026
Incidence, survival, and risk factors for first-line antiretroviral therapy failure among adults on ART follow-up in health facilities in Southwest Shoa, Oromia, Ethiopia, 2023: a retrospective cohort study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe inability of antiretroviral medications to inhibit HIV is known as antiretroviral treatment failure. One of the greatest problems facing HIV patients receiving antiretroviral therapy is treatment failure. Updated data is crucial to assess program realities and effectiveness on ART. In this study, we aimed to determine incidence, survival, and risk factors for first-line ART failure by incorporating clinical, immunological, and virologic criteria, including primary health care.
methodsA retrospective cohort study was conducted among 579 adult patients. These patients were followed between January 1, 2016, and October 2023. Double-stage cluster sampling was used. The data were entered into Epi-Data version 3.1, then cleaned and analyzed via SPSS v.25. The Kaplan–Meier curve was used to estimate the probability of first-line ART failure. The log-rank test was used to compare the time to treatment failure. The Cox proportional hazard model was used to determine predictors of first-line ART failure.
resultsThe overall incidence rate of first-line ART failure was 2.57/1000 person-months over 24,925.7 person-months of follow-up. The patients’ cumulative survival probabilities at 12 and 84 months were 100% and 76.73%, respectively. Predictor variables of first-line ART failure were male sex (AHR = 1.953; 95% CI: 1.11–3.43), disclosure of HIV infection (AHR = 0.53; 95% CI: 0.29–0.95), tuberculosis and HIV coinfections (AHR = 2.79; 95%CI: 1.33–5.87), opportunistic infections (AHR = 2.34; 95% CI: 1.23–4.28), poor/fair adherence (AHR = 3.87; 95% CI: 2.13–7.03), WHO clinical stage III/IV (AHR = 2.54; 95% CI: 1.04–6.20), and provision of CPT (AHR = 0.20; 95% CI: 0.08–0.51). CONCLUSIONS AND RECOMMENDATIONS: The low incidence of first-line ART failure suggests effective ART implementation in the region. However, first-line ART failure was significantly linked to advanced WHO stage, poor adherence, TB/HIV coinfection, male sex, lack of cotrimoxazole prophylaxis, non-disclosure of HIV status, and opportunistic infections. These findings showed the need for early monitoring, adherence support, and comprehensive care. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.